Original Article

Apoptosis induction by siRNA targeting integrin-β1 and regorafenib/DDAB-mPEG-PCL hybrid nanoparticles in regorafenib-resistant colon cancer cells

Mina Zhiani1,2,3, Mir Ali Mousavi1,2,3, Kobra Rostamizadeh4,5, Reza Pirizadeh1,2,3, Abdolreza Osali6, Afsaneh Mennati7, Behrouz Motlagh1, Mojtaba Fathi1,2

1Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran; 2Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran; 3Student Research Committee, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran; 4Zanjan Pharmaceutical Nanotechnology Research Center, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran; 5Department of Pharmaceutical Biomaterial, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran; 6Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran; 7Department of Pharmaceutical Nanotechnology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran

Received August 15, 2020; Accepted November 2, 2020; Epub April 15, 2021; Published April 30, 2021

Abstract: Colorectal cancer (CRC) is regarded as the third most common cancer worldwide. Although Regorafenib as a receptor tyrosine kinase inhibitor (RTKI) disrupts tumor growth and angiogenesis in metastatic CRC (mCRC) patients, drug resistance leads to poor prognosis and survival. Integrin-β1 overexpression has been proposed to be the major player in this regard. Herein, the Regorafenib-resistant human colon cancer cell line (SW-48) was induced, and the Integrin-β1 gene expression, as well as apoptosis, was assessed through the combination of small interfering RNA (siRNA) targeting Integrin-β1 and Regorafenib/Dimethyldioctadecylammonium bromide (DDAB)-methoxy poly (ethylene glycol) (mPEG)-poly-ε-caprolactone (PCL) hybrid nanoparticles (HNPs). In the current study, Regorafenib-resistant SW-48 cell line was generated in which the Regorafenib half-maximal inhibitory concentration (IC50) for non-resistant and resistant cells was 13.5±1.5 µM and 55.1±0.8 µM, respectively. The results of DLS also demonstrated that the size and the charge of the HNPs were equal to 66.56±0.5 nm and +29.5±1.2 mv, respectively. In addition, the Integrin-β1 gene expression was significantly higher in resistant cells than in non-resistant ones (P<0.05). The siRNA/HNP complexes in combination with Regorafenib/HNPs were accordingly identified as the most effective treatment to decrease the Integrin-β1 gene expression and to enhance the apoptosis rate in resistant cells (P<0.001). Overall, the study indicated that combination therapy using siRNA/HNP and Regorafenib/HNPs complex could down-regulate the Integrin-β1 gene expression and consequently trigger apoptosis, and this may potentially induce drug sensitivity.

Keywords: Colorectal cancer, regorafenib, integrin-β1, SiRNA, lipid-polymer hybrid nanoparticle, apoptosis

Introduction

Colorectal cancer (CRC) is regarded as the third most prevalent cancer after lung and breast cancers and has been recently reported as the second common one in some countries. It has also been the second most cancer-related mortality globally after lung cancer in 2018 [1]. Concerning the CRC development, both genetic and environmental factors are involved; however, the highest percentage of cases with this cancer is deeply associated with environmental factors. CRCs occur sporadically in the majority of cases, in which chromosomal instability (CIN), microsatellite instability (MSI), and epigenetic alterations constitute three major factors in the carcinogenic process. Furthermore, 20-25% of CRCs are familial, and only 5% are inherited forms either as familial adenomatous polyposis (FAP), Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCRC), or MYH-gene associated polyposis (MAP) [2].

More importantly, local and systemic treatments by chemotherapeutic and targeting...
agents can increase survival rates in patients [3, 4]; however, some side effects, along with resistance sound like deserve much more attention. Amongst targeting agents, the anti-vascular endothelial growth factor (VEGF)-VEGFR receptor (VEGFR) targeted therapy has emerged for the ablation of tumor angiogenesis, preventing tumor proliferation and metastasis [5]. In this respect, Regorafenib (Stivarga®) as a multiple receptor tyrosine kinase inhibitor (RTKI) can block angiogenic, stromal, and oncogenic RTKs [6], and it has even received the Food and Drug Administration (FDA) approval as the last-line therapy for metastatic CRC (mCRC) and gastrointestinal stromal tumor (GIST) [7].

Although promising progress has been obtained regarding the treatment and overall survival of CRC patients, chemotherapy-induced drug-resistance is still a challenging phenomenon in this field [8]. It should be noted that various mechanisms, such as reduction of intracellular drug concentration, genetic or epigenetic alterations [8], apoptosis inhibition, tumor microenvironments, cancer stem cells (CSCs) [9], and epithelial-mesenchymal transition (EMT) [10], contribute to CRC drug-resistance. Moreover, mechanisms of resistance to anti-angiogenic therapies are attributed to substitute vascu- logenesis systems, release of bone marrow-derived cells to tumor sites, local stromal cells [11], plethora of other angiogenic factors, and hypoxia [12]. It is believed that hypoxia is a key factor affecting resistance to Regorafenib [13] and other anti-angiogenic drugs, since it up-regulates the hypoxia-inducible factor 1-alpha (HIF-1α) and other downstream signaling pathways [14]. For example, HIF-1α induces up-regulation of Integrins, especially Integrin-β1 [12], EMT [11], and positive selection of CSCs [15].

Integrins are heterodimeric cell surface receptors [16], and they are able to transfer signals bi-directionally across membranes and participate in physiological and pathological processes. These receptors are also the drivers of stem cell-like, undifferentiated, mesenchymal phenotypes of cancer cells, inducing invasiveness, metastasis, as well as resistance in different types of cancer [17]. Integrin-β1 is also considered the greatest subset of Integrins, as it makes heterodimers with almost 2/3 of α subunits. Pre-clinical and clinical studies have further shown up-regulation and the prominent role of Integrin-β1 in the proliferation, survival, invasion, and metastatic features of tumor cells, and most importantly resistance to chemotherapy, radiotherapy, and anti-angiogenic targeted therapy [16, 18].

Likewise, genetic therapy is currently developed to treat malfunctioned protein-based diseases by alteration of DNA and ribonucleic acid (RNA) as the progenitor of such proteins. RNA interference (RNAi) mechanism is also a specific and efficient gene silencing process targeting and degrading a specific RNA within the cytoplasm, thereby down-regulating corresponding genes [19]. Despite promising features of this novel treatment, several challenges have been raised about their systemic administration. The most important obstacles comprise degradation by serum endonucleases, rapid glomerular filtration by the kidneys, aggregation with serum proteins [20], uptake by the reticuloendothelial system (RES), transmission through the vasculature, negatively charged lipid bilayer, stimulation of the innate immune system, off-target effects, and efficiency [21]. In this regard, various delivery systems have been introduced to address the aforementioned challenges. To deliver nucleic acids into cells, non-viral vectors like hybrid nanoparticles (HNPs) have received considerable attention compared to viral partners, since HNPs integrate the advantages of both polymeric and lipid-based nano-carriers [22] with the polymeric core to encapsulate hydrophobic drug and cationic lipid for nucleic acid loading [23]. Here, Dimethyldioctadecylammonium bromide (DDAB)-methoxy poly (ethylene glycol) (mPEG)-poly-ε-caprolactone (PCL) HNPs were used as biodegradable NPs with controlled release kinetics owing to the presence of PCL [24]. Furthermore, the PEG layer could enhance systemic circulation time and prevent it from renal filtration and uptaking by RES. The existence of DDAB as a cationic lipid on the shell could provide biocompatibility and facilitate siRNA delivery into cells [25].

To the best of our knowledge, the expression profile of Integrin-β1 has not been thus far evaluated in Regorafenib-resistant cell lines. Accordingly, Regorafenib-resistant human co-lon cancer cell line (SW-48) was established in this study for the first time. Then, siRNA-bearing HNPs, alone or in combination with HNPs encapsulating Regorafenib, were employed to assess such interventions on the Integrin-β1.
expression to investigate the mechanisms involved in Regorafenib-resistant cell lines. The apoptosis rate in resistant cells was also evaluated using siRNA/HNPs, alone or in combination with Regorafenib/HNPs. It was assumed that Integrin-β1 targeting siRNA in combination with Regorafenib/HNPs had the potential effect to efficiently down-regulate this gene and to promote apoptosis, thereby overcoming drug resistance.

**Materials and methods**

**Reagents and cell culture**

The SW-48 cell line (ATCC: CCL-231) was obtained from the Pasteur Institute of Iran (Tehran, Iran). Regorafenib (sc-477163) was also purchased from Santa Cruz. Integrin-β1 siRNA (sense: 5'-UAGAUAUCUCGCGUCAUACdTdT-3' and anti-sense: 5'-GUAUGACGCCAGAUAUCUAtdTdT-3') and control siRNA (sense: 5'-UA-GAUAGUCUCGCGUCAUACdTdT-3' and anti-sense: 5'-GUAUGACGCCAGAUAUCUAtdTdT-3') were synthesized by Microsynth AG (Switzerland) and Eurofins Genomics (Germany), respectively. mPEG-PCL di-block co-polymer, which had been synthesized according to the ring-opening polymerization of caprolactone in the presence of mPEG, was received as a gift from Dr. Rostamizadeh [26]. Cationic lipid DDAB (D2779 10G), 4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT), and trypan blue were purchased from Sigma-Aldrich. Moreover, centrifugal filter Vivaspin Turbo 30 MWCO was obtained from Sartorius Stedim Biotech GmbH (Germany). Gel Red TM Nucleic Acid Gel Stain was acquired from Biotium (Fremont, United States). RPMI 1640 (GIBCO, Germany), trypsin EDTA (GIBCO, Germany), Penicillin-Streptomycin (Pen-Strep) (INNOCLON, Iran), fetal bovine serum (FBS) (BIOCHROM, Germany), dimethyl sulfoxide (DMSO) (Chem Cruz), SYBER green (AMPLIQON), along with all chemicals were prepared locally. Integrin-β1 and β-actin Primers were provided from SinaGene, Iran.

**Table 1. Cycles and duration of exposure to Regorafenib for establishment of drug-resistant SW-48 cell line**

<table>
<thead>
<tr>
<th>Cycles</th>
<th>Cycle 1</th>
<th>Cycle 2</th>
<th>Cycle 3</th>
<th>Cycle 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment (Time of exposure/days)</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Recovery (Time of drug-free/days)</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

**Resistant cell-line establishment**

The sensitive cells were cultured in the RPMI 1640 medium supplemented with 10% FBS and 1% Pen-Strep in a humidified incubator at 37°C. The given cells were passaged once they reached confluency by 80%. To develop a resistant SW-48 cell line, the sensitive cells were maintained in a complete medium containing 40 μM Regorafenib for three days, and it was continued for five days without any drugs as recovery. This treatment-recovery cycle was repeated four times [27] (Table 1).

**Half maximal inhibitory concentration (IC$_{50}$) and MTT viability assay**

To confirm resistance, IC$_{50}$ of Regorafenib was measured in a non-resistant and resistant SW-48 cell line using the MTT assay. For this purpose, both groups of cells were seeded in a 96-well plate at a density of 6000 cells/well in triplicate, containing 100 μl of the complete medium supplemented with 10% FBS. After incubation for 24-48 hours at 37°C in the presence of 5% carbon dioxide (CO$_2$), the cells were washed with phosphate-buffered saline (PBS) and exposed to different doses of Regorafenib in the RPMI medium for 12 hours. Then, the supernatant was aspirated and replaced with the complete medium. After 24-hour treatment, 20 μl of the MTT solution (5 mg/ml in PBS) was added following incubation for 3-4 hours. Once the liquid was discarded, 200 μl of DMSO was added to each well to dissolve the formazan crystals. Finally, optical density (OD) was measured at 570 nm, using a plate reader. Untreated cells were considered a control group. The percentage of cell relative viability was calculated as the following formula:

$$\text{Cell relative viability} = \frac{\text{Mean OD of treated cells}}{\text{Mean OD of untreated cells}} \times 100.$$
seeded in a 96-well plate with 6000 cells per well in triplicate. After incubation for 24 hours at 37°C in the presence of 5% CO₂, the cells were washed with PBS and exposed to the RPMI medium containing 40 μM Regorafenib, for 24 hours. The MTT assay was adjusted to the protocol described in the previous section.

Preparation of DDAB-mPEG-PCL HNPs

DDAB-mPEG-PCL HNPs were synthesized using the single-step nano-precipitation method, according to the protocol reported in the previous study [26]. Briefly, 800 μl of the co-polymer stock solution (2.5 mg/ml in acetonitrile) were mixed with 200 μl of the DDAB stock solution (1 mg/ml in distilled water). Then, 7800 μl of distilled water was rapidly injected into the solution by syringes (5 ml), and the mixture was further sonicated for 6 minutes at 50°C. Synthesized HNPs were concentrated in Vivaspin filter (molecular weight cutoff of 30 KDa) through centrifugation, at 5000 rpm for 30 minutes to the final volume of 500 μl.

Preparation of Regorafenib/DDAB-mPEG-PCL HNPs

To synthesize Regorafenib/DDAB-mPEG-PCL HNPs, 800 μl of the co-polymer containing Regorafenib stock solution (2.5 mg/ml co-polymer with 0.0625 mg/ml Regorafenib in acetonitrile and DMSO as solvents) and 200 μl of DDAB stock solution (1 mg/ml in distilled water) were mixed together, and then, 7800 μl of distilled water was rapidly injected into the solution by syringes (5 ml). Subsequently, the mixture was sonicated for 6 minutes at 50°C. The concentration was carried out by Vivaspin columns.

Characterization of synthesized HNPs

Malvern Zeta sizer Nano ZS90 apparatus (Malvern Instruments, Worcestershire, United Kingdom) was used to specify the size, the surface charge, and the polydispersity index (PDI) of HNPs. However, for dilution purposes, the OD of HNPs was measured in 633 nm, using a spectrophotometer.

Preparation of siRNA-loaded HNPs and gel retardation assay

To fulfill efficient delivery, certain amounts of the HNPs were combined with a fixed concentration of siRNA (52 ng) to form siRNA/HNP complexes with different ratios of positively charged polymer amine nitrogen (N) to negatively charged nucleic acid phosphate (P) (N/P ratio). The volume of the HNPs employed was as follows:

\[ \text{Volume of HNPs (μl)} = \frac{\text{μg of siRNA} \times \text{nmol of phosphate per 1 μg} \times \text{N/P ratio/nmol of nitrogen in cationic lipid per 1 μg}}{1} \]

It should be noted that there are 3 nmol of phosphate in one microgram of siRNA and 0.634 nmol of nitrogen in one microgram of DDAB as a cationic lipid. Therefore, various N/P ratios need different volumes of HNPs.

For HNP/siRNA complex formation, the mixtures were incubated for 1 hour at room temperature. SiRNA/HNP complexes were then run on a 2% agarose gel for gel retardation assay at a constant voltage of 120 V for 30-45 minutes in tris-borate-EDTA (TBE) 1× buffer and stained with Gel Red dye developed using UV-Transilluminator (Analytic Jena AG). Free siRNA was also used as a positive control.

Determination of siRNA encapsulation efficiency

Optimized volumes of HNPs were mixed with siRNA and incubated for 1 hour at room temperature to form the complex, which was then centrifuged at 5000 rpm for 5 minutes. The absorbance of the total amount of siRNA and free siRNA, which had been already passed through the filter, was also measured by a Nanodrop at 260 nm to evaluate the encapsulation efficiency. The following formula was utilized for the encapsulation efficiency (EE) calculation:

\[ \text{EE} = \frac{\text{total amount of siRNA-free siRNA in underlaid solution}}{\text{total amount of siRNA}} \times 100 \]

Treatments and siRNA delivery by HNPs

To evaluate the effects of siRNA/HNPs and Regorafenib/HNPs on the Integrin-β1 gene silencing and apoptosis of cancer cells, 3.5×10⁵ cells were seeded into 6-well plates, containing 2 ml of enriched media, and incubated for 48 hours at 37°C. Then, different concentrations of siRNA (25, 50, and 100 nM) and Regorafenib (40 μM), their HNP complexes, as well as their
Table 2. Treatment groups of resistant SW-48 cells and different doses of siRNA, siRNA/HNPs, free drug, and drug-loaded HNPs

<table>
<thead>
<tr>
<th>Group</th>
<th>Sub-group</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) SiRNA</td>
<td>A1: siRNA 100</td>
</tr>
<tr>
<td></td>
<td>A2: siRNA 50</td>
</tr>
<tr>
<td></td>
<td>A3: siRNA 25</td>
</tr>
<tr>
<td>B) SiRNA/HNP</td>
<td>B1: SiRNA/HNP 100</td>
</tr>
<tr>
<td></td>
<td>B2: SiRNA/HNP 50</td>
</tr>
<tr>
<td></td>
<td>B3: SiRNA/HNP 25</td>
</tr>
<tr>
<td>C) Drug40+siRNA/HNP</td>
<td>C1: Drug 40+SiRNA/HNP 100</td>
</tr>
<tr>
<td></td>
<td>C2: Drug 40+SiRNA/HNP 50</td>
</tr>
<tr>
<td></td>
<td>C3: Drug 40+SiRNA/HNP 25</td>
</tr>
<tr>
<td>D) NPD40+siRNA/HNP</td>
<td>D1: NPD40+siRNA/HNP 100</td>
</tr>
<tr>
<td></td>
<td>D2: NPD40+siRNA/HNP 50</td>
</tr>
<tr>
<td>E) others</td>
<td>E1: SiRNA control/HNP 100</td>
</tr>
<tr>
<td></td>
<td>E2: NP100</td>
</tr>
<tr>
<td></td>
<td>E3: Drug 40</td>
</tr>
<tr>
<td></td>
<td>E4: NPD40</td>
</tr>
<tr>
<td></td>
<td>E5: NPD20</td>
</tr>
<tr>
<td>F) control</td>
<td>F: untreated resistant cells</td>
</tr>
</tbody>
</table>

Real-time polymerase chain reaction (RT-PCR)

For this purpose, 1 μl of synthesized cDNA was combined with 0.5 μl of each Forward/Reverse primer as well as deionized water and RealQ Plus Master Mix Green (AMPLIQON). The PCR reaction was conducted using the ABI (Step-OnePlus) system. The sequences of the Integrin-β1 primers were Forward: 5’ TGATTGGCT-GAGGGAAATTGTA 3’ and Reverse: 5’ GTTTCTGG-GACAAGGGTGGCAA 3’. β-actin was additionally recruited as the housekeeping control gene, and the primer sequences were Forward: 5’ ACTTCTGCCCTTTTCTTC 3’ and Reverse: 5’ CTACAGGTCTTGGGGATG 3’. PCR production length was 186 bp for Integrin-β1 and 104 bp for β-actin. The PCR cycling condition consisted of an initial activation step at 95°C for 15 minutes and 40 cycles of 95°C for 15 seconds (sec), 60°C for 30 sec, and 72°C for 30 sec. The relative expression level of Integrin-β1 was further normalized to β-actin and untreated control group levels. Ultimately, the fold change was calculated using the E^-ΔΔCT formula to represent the data. To ensure the quality of the products, RT-PCR aliquots were run on 2% agarose gel electrophoresis and then visualized using an UV set after being dye-stained.

Apoptosis assay and flow cytometry (FC)

The transfection of the resistant cells was performed as just described for the Integrin-β1 expression assay using RT-PCR. Cell apoptosis assay was conducted according to the protocol of the FITC Annexin V Apoptosis Detection Kit (Invitrogen/eBioscience), 56 hours after transfection. Briefly, the cells were trypsinized and washed with cold PBS and 1× binding buffer. Subsequently, the cell suspension in the 1× binding buffer was prepared at the concentration of 1×10^6/ml. Then, 2.5 μl of FITC Annexin V was added to 100 μl of the cell suspension and further incubated for 10-15 minutes at RT. After being washed with 1× binding buffer, the cells were resuspended in 200 μl binding buffer, and 2.5 μl of propidium iodide (PI) was added to the samples. The rate of apoptosis was assessed using the BD FACS Calibur instrument. Both early apoptotic (Annexin V-positive and PI-negative) and late apoptotic (Annexin V-positive and PI-positive) cells were considered total apoptosis determinants. The results
Co-delivery of Integrin-β1 siRNA and Regorafenib to overcome cancer resistance

Figure 1. Cell survival percentage in the SW-48 cell line at the end of each cycle using the MTT method. The cells were treated for four cycles by Regorafenib, and then the MTT assay was conducted. They experienced a high rate of mortality in the early cycles, but adapted to the environment and exhibited more viability at the end of cycles 3 and 4. According to the Tukey’s post-hoc test of multiple comparisons, significant differences were observed between each cycle, cycle 1 and the non-resistant group. **P=0.0017, ***P<0.0001.

were analyzed by the FlowJo software. However, the flow cytometer was calibrated using instrument-related fluorescence beads to obtain accurate data. The control cells (namely, unstained and stained) were also employed to adjust the fluorescence threshold.

Statistical analysis

Statistical analysis was performed using the IBM SPSS Statistics software (version 24), and the related graphs were drawn by GraphPad Prism 8.0.1. Kolmogorov-Smirnov and Shapiro-Wilk tests were conducted to assess normal distribution. To compare the differences between the resistant and non-resistant variables, an independent-samples t-test was performed. One-way analysis of variance (ANOVA) with Tukey’s post-hoc test was also conducted to compare the differences between multiple treatments. All the data were expressed as the mean ± standard deviation (SD), and p-value <0.05 was considered statistically significant.

Results

Establishment of regorafenib-resistant SW-48 cell line

To confirm the development of resistant SW-48 cells, the MTT assay was performed. As Figure 1 shows, the cell viability percentage at the end of the eighth day was 73.8±7.9% in cycle 1, 86.8±3.1% in cycle 2, 90.2±0.9% in cycle 3, and 92.3±0.8% in the last cycle. Cell viability in all of the cycles was significantly decreased after the Regorafenib treatment compared to the control cells. Once the cycles were analyzed, a significant increase in cell viability was observed from the first cycle toward the last one, indicating the adaptation of the cells to the drug. In addition, the IC\textsubscript{50} of Regorafenib was measured in resistant and non-resistant cells, using the MTT method. As Figures 2 and 3 display, the IC\textsubscript{50} was 13.5±1.5 μM for non-resistant cells, but it augmented to 55.1±0.84 μM in resistant ones, indicating that the cells could tolerate the drug owing to resistance and adaptation.

DDAB-mPEG-PCL HNPs and regorafenib/HNPs characterization

The DDAB-mPEG-PCL HNPs and Regorafenib/HNPs were prepared using the single-step nano-precipitation method. Dynamic light scattering (DLS) was further used to control the quality of the HNPs. As Table 3, and Figure 4A and 4B show, Z-average size, zeta potential, and PDI of
Co-delivery of Integrin-β1 siRNA and Regorafenib to overcome cancer resistance

DDAB-mPEG-PCL HNPs were 66.56±0.5 nm, +29.5±1.2 mv, and 0.327±0.08, respectively. As Figure 5A and 5B illustrate, Z-average size, zeta potential, and PDI of Regorafenib-loaded HNPs were also equal to 68.25±1.1 nm, +26.9±0.6 mv, and 0.371±0.04, respectively.

SiRNA/HNP complex formation

Figure 3. Inhibitory effect of Regorafenib on the cell viability of resistant SW-48 cells in a dose-dependent manner. Cell viability was measured using the MTT method by incubating the cells to the increasing doses of Regorafenib (0-60 μM) for 24 hours. The IC_{50} was 55.1±0.84 μM in resistant cells.

Gel retardation assay was conducted to confirm the formation of siRNA/HNP complexes and to determine the optimum N/P ratio for maximum efficacy. Therefore, HNPs and siRNA were combined at the ratio of 0-60 to form the complexes. After being incubated for 1 hour, the samples were run on 2% agarose gel. The wells related to the N/P ratios of 2-15 exhibited obvious bands similar to the control one, while there was no band on the well related to the N/P ratio of 20. Thus, the N/P ratio of 20 was selected as the best N/P ratio, since higher N/P ratios than 20 result in more cytotoxicity to the cells (Figure 6).

SiRNA encapsulation efficiency of HNPs

Ultrafiltration of the siRNA/HNP complexes at the N/P ratio of 20 was obtained using gel retardation assay. Then, the absorbance of the total amount of siRNA added to the HNP and free siRNA passed through the Vivaspin column was measured at 260 nm. siRNA encapsulation efficiency was further calculated to be 98.7% at the N/P ratio of 20. Hence, the majority of siRNA molecules were tightly attached to the NP via different interactions, especially electrostatic bond ones.

Integrin-β1 expression in resistant and non-resistant SW-48 cell lines

The Integrin-β1 gene expression level was measured in resistant cells using RT-PCR and then compared to non-resistance. The analysis of the obtained cycle threshold (CTs) showed a significant difference in the Integrin-β1 mRNA level between resistant and non-resistant cells (P<0.05). In this regard, the changes in the mRNA folds in resistant cells were 1.81 times as much as non-resistant ones (Figure 7), confirming the Integrin involvement in cancer resistance.

Down-regulation of integrin-β1 using a combination of sirna/hnps and regorafenib/hnps in resistant sw-48 cells

Statistically, the data analysis demonstrated that the use of free siRNA, HNPs, and control siRNA did not influence the Integrin-β1 gene expression. However, B1 (siRNA-HNP with 100 nM of siRNA) and B2 (namely, siRNA-HNP with 50 nM of siRNA) subgroups (in the B group) significantly diminished the Integrin-β1 mRNA level compared to the control group (P<0.01), demonstrating the importance of HNPs in siRNA delivery. Combination therapy with D40 (Regorafenib 40 μM) and siRNA/HNPs as well as NPD40 (HNP bearing 40 μM of Regorafenib) and siRNA/HNPs showed different results. Accordingly, the C1 subgroup exhibited the most significant effects on the Integrin-β1 mRNA level down-regulation (P<0.001). Furthermore, the combination of NPD40 and siRNA/HNPs either by D1 or D2 sub-groups significantly mitigated the mRNA level (P<0.001). The NPD40 with siRNA/HNP 100 was also found as the most effective treatment in decreasing the Integrin-β1 gene expression. In other words, Regorafenib-loaded HNPs, along with siRNA/HNPs had the highest capacity to down-regulate the Integrin-β1 gene. Overall, HNPs facilitated siRNA and drug delivery into cancer cells, and the combination of both targeting agents exhibited synergistic effects on the cells (Figures 8 and 9).
Table 3. Size distribution, zeta potential, and PDI of DDAB-mPEG-PCL HNPs and Regorafenib loaded HNPs

<table>
<thead>
<tr>
<th>NP</th>
<th>Size (nm) ± SD</th>
<th>Zeta potential (mV) ± SD</th>
<th>PDI ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDAB-mPEG-PCL HNPs</td>
<td>66.56±0.5</td>
<td>+29.5±1.2</td>
<td>0.327±0.08</td>
</tr>
<tr>
<td>Regorafenib-loaded HNPs</td>
<td>68.25±1.1</td>
<td>+26.9±0.6</td>
<td>0.371±0.04</td>
</tr>
</tbody>
</table>

The FC results showed that using siRNA alone did not influence the apoptosis rate, while siRNA/HNP 100 nM could enhance it by 22.27±0.61%. The combination therapy of D40 with siRNA/HNP 100 nM also induced apoptosis by 37±1.6%. In this respect, NPD40 with siRNA/HNP 100 nM had the most significant effects on the apoptosis of resistant cells by 85.4±1.7% (P<0.001). Simply put, Regorafenib could trigger the apoptosis signaling in the cell through down-regulation of the Integrin-β1 gene by siRNA/HNPs (Figures 10 and 11).

Discussion

Drug resistance to anti-angiogenic therapies like Regorafenib deserves further attention due to its effects on survival rates in metastatic patients. Accordingly, studies have revealed that one of the main mechanisms related to resistance to these agents correlates with hypoxia and HIF-1α up-regulation [28]. In this respect, HIF-1α activates the cMET-HGF signaling pathway, up-regulates the Integrin-β1 gene expression, and induces malignant phenotypes in cancer [12]. Therefore, the Integrin-β1 gene silencing by siRNA can be an effective and specific method to combat such resistance. Here, the Regorafenib-resistant SW-48 cell line mimicking in vivo cancer resistance was established according to previous experiments. This report demonstrated that anti-Integrin-β1 siRNA and Regorafenib to overcome cancer resistance
Co-delivery of Integrin-β1 siRNA and Regorafenib to overcome cancer resistance

β1 siRNA using DDAB-mPEG-PCL HNPs as a carrier had the potential to down-regulate the Integrin-β1 gene, resulting in releasing the apoptosis pathway that could be induced via combination with Regorafenib/HNPs.

In the previous study, a gradual method was used to develop the resistant SW-48 cell line considering that resistance could enrich cancer stem cells [29]. In this study, resistant SW-48 cells were induced by exposing them to Regorafenib using the cyclic method [27] to describe that cancer cells could tolerate chemotherapeutic agents, and the mode of exposure was unimportant. The IC_{50} of Regorafenib was additionally increased in resistant cells compared to non-resistant ones, and the viability of the cells was enhanced with the time of receiving the drug, implying the adaptation of the cells to the drug. Although IC_{50} has indicated different values in various studies on investigated cancer resistant cells, it has usually been higher in resistant cancer cells than that in non-resistant ones. Given that cancer cells have genome instability and heterogeneity, these differences in IC_{50} among various studies may be attributed to various cell lines, resistance induction protocols, passage number of cells, drug concentrations, origins of cells, and so forth.

The DDAB-mPEG-PCL HNPs and Regorafenib/HNPs were synthesized in this study using the single-step nano-precipitation method, as described by Fang [30]. The Z-average size of the prepared DDAB-mPEG-PCL HNPs was 66.56±0.5 nm, which is appropriate for the systemic delivery of siRNA to the tumor site. Moreover, these HNPs had the zeta potential of +29.5±1.2 mv for effective encapsulation of siRNA and cellular uptake.

The N/P ratio of the siRNA/DDAB-mPEG-PCL complexes was 20. Lu Y investigated 1,2-dioleyloxy-3-(trimethylammonium) propane (DOTAP)-conjugated mPEG-PCL (DMP) NP to bring myeloid cell leukemia 1 (Mcl-1) and B-cell lymphoma-extra-large (Bcl-xL) siRNA into CRC cells. The size of this nano-micelle was 144.8 nm with the zeta potential of +46.4 mv and the N/P ratio equal to 30. Thus, it was concluded that siRNA-loaded DMP micelles could decrease gene expression and trigger apoptosis, thereby inhibiting tumor growth in C26 cells and in vivo xenograft models [31].

Yang used N,N-bis(2-hydroxyethyl)-N-methyl-N-(2-cholesteryloxy carbonylaminoethyl) ammoni-
umbromide (BHEM-Chol)/mPEG-PLA HNPs to deliver polo-like kinase 1 (PLK-1) specific siRNA into the human breast cancer (BT-474) cell line with the particle size of 110 nm, the zeta potential of +50 mV (in lipid/polymer weight ratio of 0.1), and the N/P ratio of 5. These HNPs had high encapsulation efficiency up to 90% and were also able to down-regulate the PLK-1 gene considerably, induce apoptosis, and decline tumor growth in vitro and in vivo [32].

The N/P ratio describes the relative numbers of positive charges, present on the NP for efficient binding with the negatively charged cell membrane. Thus, it could play a pivotal role in the cell uptaking of the cargo. It appears that the size and the zeta-potential can directly affect the N/P ratio. Furthermore, in a previous study conducted to investigate the delivery efficiency of PLA-PEG-PLA tri-block copolymer and DDAB, the N/P ratio was obtained in 60 [26].

Figure 8. Comparison of the Integrin-β1 gene expression level in different treatment groups of resistant SW-48 cells. The use of free siRNA did not significantly affect Integrin-β1 gene expression (A). Significant differences were observed in the subgroups of (B-D) compared to the untreated control group. (E) Comparison of the effect of Regorafenib-loaded HNPs and free Regorafenib on the Integrin-β1 gene expression. HNPs and siRNA negative control/HNPs were used as controls. **P<0.01, ***P<0.001.
Accordingly, different structures in the polymer and cationic lipid may play a crucial role in the distribution and organization of charges and ultimately the N/P ratio.

In addition, activation of Integrin-β1 downstream signaling pathways results in apoptosis resistance, survival, proliferation, invasion, and metastasis of cancer cells [16, 33]. Tumor microenvironment, cancer stem cells [34], and EMT [10] are the major contributors to the Integrin-β1 function to induce cancer drug resistance. Different studies have also demonstrated the up-regulation of Integrin-β1 in response to resistance to radiotherapy, chemotherapy, targeted therapy, and anti-angiogenic drugs [33, 35, 36]. For example, Michael DeLay found the Integrin-β1 4-fold overexpression in the clinical samples of bevacizumab-resistant patients, and similarly Carbonell demonstrated the 8-fold up-regulation of this protein in Bevacizumab-treated BRG cells [28, 37]. However, there is no study evaluating the Integrin-β1 expression in Regorafenib-resistant SW-48 cell lines. The results of the present study indicated that the Integrin-β1 gene expression could increase by 1.81 times in resistant cells than in non-resistant ones.

Integrin-β1 as the largest subgroup of Integrins [16] may be compared to the β subunits of human chorionic gonadotropin (hCG), which is a dominant contributor in the tumors derived from embryonic stem cells. Integrin-β1 is possibly a major player in the deviation of cancer stem cells from original tumor ones and may be introduced as a therapeutic target to disrupt the hallmarks of resistant cancer. In line with these experiments, Mu investigated the effect of anti-c-Jun N-terminal kinase-1 (Jnk-1) siRNA using 1,2-Distearoyl-sn-glycero-3-phosphorylthanolamine (DSPE)/PEG-PEI-PLGA NPs in the human prostate cancer (DU145) cell line, and concluded that it could induce the apoptosis; however, no combination therapy with chemotherapeutic agents was utilized [38]. To achieve the maximum effect of Integrin-β1 siRNA, different concentrations were tested, confirming that the combination of siRNA/HNPs with Regorafenib/HNPs was the most effective treatment in decreasing the Integrin-β1 gene expression and the apoptosis induction in resistant cells. The results of this study indicated that the Integrin-β1 mRNA level was significantly decreased, when the resistant cells were treated with the combination of siRNA/HNP and Regorafenib/HNPs. The results demonstrated...
Figure 10. Effect of Integrin-β1 siRNA 100 (A), siRNA-HNP 100 (B), D40+siRNA-HNP 100 (C), and NPD40+siRNA-HNP 100 (D) on the apoptosis rate of resistant SW-48 cells detected by FC. Q1, Q2, Q3, and Q4 quadrants represent necrotic, early apoptotic, late apoptotic, and normal cells, respectively. (E) show the control group (i.e., untreated group).
that the release of Integrin-β1-mediated anti-apoptosis could be challenged by specific siRNA, which could finally lead to the effectiveness of Regorafenib. Dong indicated that down-regulation of survivin in combination with Paclitaxel and Epirubicin in the resistant breast cancer cell line (MCF-7) could trigger apoptosis, decrease cell proliferation, and reverse the resistance process [39].

Resistance to targeted therapy through Integrin-β1 in solid tumors occurs via different mechanisms. In addition, Integrin-β1 can employ RTKs or other co-receptors to develop such resistance. Despite the prominent therapeutic role of Integrin-β1, the complicated and heterodimeric structure of these glycoproteins as well as the role of α sub-units should be considered. Using Integrin-β1 as a therapeutic target in combination with chemotherapeutic drugs is also a promising method to classify patients, reduce dosage of therapeutic agents, enhance the effect of chemotherapy, and minimize side effects.

Conclusion

Induction of resistant SW-48 CRC cell lines attenuated the anti-cancer effects of Regorafenib and up-regulated the Integrin-β1 gene expression in these cells. The study also signified the role of combination therapy using siRNA/HNPs with Regorafenib/HNPs to down-regulate the Integrin-β1 gene expression and induce apoptosis remarkably in resistant cells, which might influence the Regorafenib-resistant signaling pathway.

Acknowledgements

This study was funded by grants (A-12-802-23 and A-12-802-27) from Zanjan University of Medical Sciences (ZUMS), School of Medicine, Cancer Gene Therapy Research Center, and Department of Clinical Biochemistry.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Mojtaba Fathi, Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. Tel: +982433140289; Fax: 451395-6111; E-mail: m_fathi@zums.ac.ir

References

Co-delivery of Integrin-β1 siRNA and Regorafenib to overcome cancer resistance


Co-delivery of Integrin-β1 siRNA and Regorafenib to overcome cancer resistance


